Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia
Authors:
- 4 July 2023
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 34 (9) , 796-805
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemiaBlood, 2015
- Association of Advanced Leukemic Stage and Skin Cancer Tumor Stage With Poor Skin Cancer Outcomes in Patients With Chronic Lymphocytic LeukemiaJAMA Dermatology, 2014
- T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine productionBlood, 2013
- Chronic Lymphocytic Leukemia Is Associated With Decreased Survival of Patients With Malignant Melanoma and Merkel Cell Carcinoma in a SEER Population-Based StudyJournal of Clinical Oncology, 2012
- Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based studyBritish Journal of Cancer, 2011
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Effects of Chronic Lymphocytic Leukemia on the Development and Progression of Malignant MelanomaDermatologic Surgery, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukemiaLeukemia, 2005